Core Viewpoint - LifeMD, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and increased customer acquisition costs [1][3]. Financial Performance - On August 5, 2025, LifeMD reported its second quarter 2025 results, indicating that customer acquisition costs rose by 5% to 25% compared to the previous quarter, impacting the business negatively [3]. - The company's transition into the weight management space was highlighted as a significant factor in the increased costs, with analysts suggesting that management lost focus on customer acquisition for its RexMD platform [3]. Stock Market Reaction - Following the announcement of the second quarter results, LifeMD's stock price experienced a significant decline, falling by $5.31 per share, or 44.84%, closing at $6.53 per share on August 6, 2025 [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims & Hers Health, Inc. spans from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements made by the defendants about the company's business and operations lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for August 25, 2025 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over- the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleadin ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 [5]

Core Viewpoint - Hims & Hers (NYSE: HIMS) is considered one of the most undervalued growth stories in the telehealth sector, with a reported Q2 revenue of $545 million, reflecting a 73% year-over-year increase, positioning the company for an annual revenue of $2.4 billion [1] Company Summary - Hims & Hers reported Q2 revenue of $545 million, which is a 73% increase compared to the previous year [1] - The company is on track to achieve an annual revenue of $2.4 billion [1] Industry Context - The telehealth industry is experiencing significant growth, with companies like Hims & Hers leading the way in terms of revenue increases and market potential [1]

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns related to its products [1][2]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [2]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [2]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Investor Actions - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [3]. - A lead plaintiff acts on behalf of all class members and selects counsel to represent the class in litigation [3]. - Investors can choose to remain absent from the class action without affecting their ability to share in any recovery [3]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [4].

Core Insights - Hims & Hers Health, Inc. (HIMS) is focused on democratizing access to personalized healthcare, particularly in underserved areas, with a subscriber base of 2.4 million and nearly 1,500 licensed providers by Q2 2025 [1][7] - The company is expanding into hormonal health, targeting menopause and low testosterone, which presents a significant market opportunity in the U.S. [2][7] - International expansion through the acquisition of ZAVA enhances Hims & Hers' presence in Europe, gaining access to over 1.3 million patients, with plans to enter Canada in 2026 [3][7] Market Performance - Hims & Hers shares have increased by 86.5% year-to-date, outperforming the industry growth of 23.5% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 3.8X, lower than the industry average of 5.8X but higher than its three-year median of 2.4X [8] Financial Estimates - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a 137% improvement from 2024 [9] - Current consensus estimates for HIMS' earnings per share are 0.12 for Q3 2025, 0.14 for Q4 2025, 0.64 for the current year, and 0.89 for the next year [12]

While LifeMD (NASDAQ: LFMD ) continues to record strong growth from its telehealth platforms, dual misses for its fiscal 2025 second quarter have led investors to revise previous estimates for growth downwards. I'm more neutral on the commons The equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high- ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for allegedly making false statements and engaging in deceptive practices related to the promotion and sale of Wegovy®, leading to a significant drop in stock price after the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, to seek lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2][3]. - Following the announcement of the partnership termination by Novo Nordisk on June 23, 2025, Hims & Hers' stock price fell by more than 34% [3]. Group 2: Company Background - Hims & Hers is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, due to these deceptive practices, leading to a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the class period (April 29, 2025, to June 23, 2025) can seek to be appointed as lead plaintiff in the lawsuit [4] - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 [5]